Literature DB >> 14675313

Comparison of HGF (hepatocyte growth factor) levels of epithelial ovarian cancer cyst fluids with benign ovarian cysts.

C Baykal1, E Demirtas, A Al, A Ayhan, K Yuce, G Tulunay, M F Kose, A Ayhan.   

Abstract

Hepatocyte growth factor (HGF) is known to take a role in oncogenesis and tumoral behavior of the tumors of the organs that contain both mesenchymal and epithelial cells. This study compares HGF levels in cyst fluids of epithelial ovarian cancer and benign ovarian cysts to look for the role of HGF in ovarian carcinogenesis. Twenty-four consecutive patients with ovarian cancer and 34 with benign ovarian cysts were recruited prospectively at the Gynecologic Oncology Departments of SSK Ankara Maternity Hospital and Hacettepe University School of Medicine between 2001 and 2002. Cyst fluids were collected during primary staging in cancer patients and during laparatomy for benign patients. HGF levels were measured by ELISA method. Median HGF levels of the benign ovarian cysts and epithelial ovarian tumoral fluids were found to be 3822 pg/ml (85-15253 pg/ml) and 12962 pg/ml (4136-16025 pg/ml), respectively. Malignant cyst fluids have higher HGF levels when compared with benign ovarian cysts (P < 0.01). This finding suggests that HGF may take a paracrine role in oncogenic differentiation and tumoral development of epithelial ovarian cancers. Mechanisms that take a role in HGF secretion and the responses of neighboring epithelial cells to HGF during tumoral development need to be investigated.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14675313     DOI: 10.1111/j.1525-1438.2003.13326.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  6 in total

1.  Transcriptional profiling analysis predicts potential biomarkers for glaucoma: HGF, AKR1B10 and AKR1C3.

Authors:  Qiaoli Nie; Xiaoyan Zhang
Journal:  Exp Ther Med       Date:  2018-10-17       Impact factor: 2.447

2.  c-Met overexpression contributes to the acquired apoptotic resistance of nonadherent ovarian cancer cells through a cross talk mediated by phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1/2.

Authors:  Maggie K S Tang; Hong Y Zhou; Judy W P Yam; Alice S T Wong
Journal:  Neoplasia       Date:  2010-02       Impact factor: 5.715

Review 3.  Cell-cell and cell-matrix dynamics in intraperitoneal cancer metastasis.

Authors:  Katharine L Sodek; K Joan Murphy; Theodore J Brown; Maurice J Ringuette
Journal:  Cancer Metastasis Rev       Date:  2012-06       Impact factor: 9.264

4.  INC280, an orally available small molecule inhibitor of c-MET, reduces migration and adhesion in ovarian cancer cell models.

Authors:  Kim Moran-Jones; Laura M Brown; Goli Samimi
Journal:  Sci Rep       Date:  2015-07-03       Impact factor: 4.379

5.  MET/HGF Signaling Pathway in Ovarian Carcinoma: Clinical Implications and Future Direction.

Authors:  Paulette Mhawech-Fauceglia; Michelle Afkhami; Tanja Pejovic
Journal:  Patholog Res Int       Date:  2012-12-25

6.  High-grade serous ovarian cancer cell lines exhibit heterogeneous responses to growth factor stimulation.

Authors:  Danielle L Bourgeois; Karl A Kabarowski; Veronica L Porubsky; Pamela K Kreeger
Journal:  Cancer Cell Int       Date:  2015-12-07       Impact factor: 5.722

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.